Acute Porphyria Drug Database

B01AC07 - Dipyridamole
Not porphyrinogenic
NP

Rationale
No CYP-interactions. Three references consider it safe.
Chemical description
Platelet inhibitor administered as tablets in a dose of 200 mg, Maximal plasma levl is 2.6 ug/mL. In main parts excreted unmetabolized in faeces. Metabolism takes place by conjugation with glucuronic acid. South African list: Use. French list: Authorized. Michael Moore’s list: safe. C.Andersson; patient reports: tolerated (n=1)
IPNet drug reports
Uneventful use reported in 1 patients with acute porphyria.

Similar drugs
Explore alternative drugs in similar therapeutic classes B01A / B01AC or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙